Weidl Daniel, Capper David, Onken Julia, Liu Ilon, Glaser Doris, Orben Felix, Eberle Karolin, Coburger Jan, Bullinger Lars
Servier Deutschland GmbH, Munich, Germany.
Department of Neuropathology, Charité - Universitätsmedizin Berlin (CCM), Berlin, Germany.
J Neurooncol. 2025 May 13. doi: 10.1007/s11060-025-05068-z.
This study provides a comprehensive analysis of the real-world epidemiology of histologically assessed IDH-mutated or IDH-wildtype grade II and III gliomas in Germany between 2009 and 2021, supplemented with a literature-based approach of setting the data in the context of the WHO 2021 classification.
Data from the Centre for Cancer Registry Data (ZfKD) at the Robert Koch-Institute (RKI) was utilized, encompassing all incident cases of histologically (according to the WHO classification of the respective time) newly diagnosed grade II and III gliomas diagnosed between 2009 and 2021, representing a subgroup of the total number of 14,053 glioma cases (including high grade glioma). Data were supplemented with an exploratory literature review on IDH-mutation rates and epidemiology data from the German low-grade glioma (LoG-Glio) disease registry.
The tumor class distribution of newly diagnosed gliomas showed the majority being classified as grade IV glioma and only 9.0% and 9.2% as grade II or III, respectively. The incidence remained stable over the observation period. Literature data indicate mutation rates of IDH of approximately 86% in grade II and 60% in grade III gliomas diagnosed using pre-WHO-2021 criteria. Applying these proportions to 2009-2021 mean incidence cases numbers in an estimate of 459 grade 2 and 328 grade 3 IDH-mutated gliomas (combining astrocytoma and oligodendroglioma) and an incidence rate of 0.6 and 0.5 per 100.000 population for newly diagnosed IDH-mutated gliomas in Germany.
This study gives an overview of the incidence of WHO grade 2 and grade 3 gliomas among the German population. Furthermore, this study highlights the need of molecular information being integrated into epidemiologic monitoring of gliomas to obtain more precise insights into survival and prognostic factors.
本研究对2009年至2021年间德国组织学评估的异柠檬酸脱氢酶（IDH）突变型或IDH野生型二级和三级胶质瘤的真实世界流行病学进行了全面分析，并采用基于文献的方法将数据置于世界卫生组织（WHO）2021年分类的背景下。
利用了罗伯特·科赫研究所（RKI）癌症登记数据中心（ZfKD）的数据，涵盖了2009年至2021年间组织学上（根据相应时间的WHO分类）新诊断的二级和三级胶质瘤的所有发病病例，这些病例是14,053例胶质瘤病例（包括高级别胶质瘤）总数的一个亚组。数据还补充了关于IDH突变率的探索性文献综述以及来自德国低级别胶质瘤（LoG-Glio）疾病登记处的流行病学数据。
新诊断的胶质瘤的肿瘤类别分布显示，大多数被分类为四级胶质瘤，二级和三级分别仅占9.0%和9.2%。在观察期内发病率保持稳定。文献数据表明，使用WHO 2021年之前的标准诊断的二级胶质瘤中IDH突变率约为86%，三级胶质瘤中约为60%。将这些比例应用于2009 - 2021年的平均发病病例数，估计有459例二级和328例三级IDH突变型胶质瘤（合并星形细胞瘤和少突胶质细胞瘤），德国新诊断的IDH突变型胶质瘤的发病率分别为每10万人0.6例和0.5例。
本研究概述了德国人群中WHO二级和三级胶质瘤的发病率。此外，本研究强调了将分子信息纳入胶质瘤流行病学监测以更精确了解生存和预后因素的必要性。
